Antonio Terrelonge
Family Medicine · Miami, FLNPI 1386757102
Payments from drug & device makers
Across 285 payments — averaging $11,212 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1.1M
- GSK$735K
- Sumitomo Pharma America, Inc.$320K
- AbbVie$180K
- Eli Lilly$177K
- Merck$143K
- plus $522K from 15 others
Across 13 payments — averaging $1493.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$18K
- GSK$1K
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $1,119,591 |
| GSK | 90 | $735,350 |
| Sumitomo Pharma America, Inc. | 15 | $319,606 |
| AbbVie | 39 | $179,648 |
| Eli Lilly | 6 | $176,548 |
| Merck | 6 | $142,601 |
| Novartis | 9 | $122,728 |
| Regeneron | 22 | $112,268 |
| Pfizer | 16 | $74,793 |
| Ironwood Pharmaceuticals, Inc | 12 | $61,956 |
| Paratek Pharmaceuticals, Inc. | 3 | $36,312 |
| Boehringer Ingelheim Canada Ltd.ltee | 33 | $30,283 |
| Boehringer Ingelheim | 3 | $20,943 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $18,724 |
| Chiesi USA, Inc. | 6 | $10,816 |
| Bristol Myers Squibb | 1 | $9,500 |
| Akebia Therapeutics Inc | 12 | $8,801 |
| Bayer | 1 | $6,000 |
| Novo Nordisk AS | 2 | $5,045 |
| AstraZeneca | 1 | $3,829 |
| Janssen Research & Development, LLC | 1 | $52 |
How this compares
$3,195,394 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $30,284 |
| FarxigaDapagliflozin Propanediol | 29 | $23,040 |
| EliquisApixaban | 25 | $21,841 |
| XareltoRivaroxaban | 25 | $17,035 |
| BrilintaTicagrelor | 29 | $15,587 |
| SynjardyEmpagliflozin/Metformin Hcl | 22 | $15,299 |
| LinzessLinaclotide | 14 | $14,347 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 22 | $13,129 |
| JardianceEmpagliflozin | 14 | $12,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,439 |
| PremarinEstrogens, Conjugated | 18 | $10,376 |
| TradjentaLinagliptin | 16 | $10,242 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $6,952 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,271 |
| Ciclopirox | 36 | $1,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy, Trijardy Xr, Jardiance, Tradjenta | $20,943 | $51,38074 claims |
| AstraZenecaFarxiga, Brilinta | $3,829 | $38,62758 claims |
| PfizerEliquis, Premarin | $74,793 | $32,21743 claims |
| AbbVieLinzess | $179,648 | $14,34714 claims |
| GSKTrelegy Ellipta | $735,350 | $10,43914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- David WyattMiami$13.7M
- Jose CardenasMiami$13.2M
- Lazaro GarciaMiami$10.3M
- Ibrahim Menendez PerezMiami$8.9M
- Aniel Navarro MarinMiami$7.3M
- Gilberto SecoMiami$6.8M
- Ramon LeonMiami$6.3M
- Eddy CapoteMiami$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.